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ABSTRACT 
To report the efficacy of combination therapy (bevacizumab and photocoagulation) in a case of Eales 
Disease this study has been performed. Bevacizumab (Avastin, 1.25 mg/0.05 ml) was injected 
intravitreously for the treatment of iris and retinal neovascularization in a 56-year old Hispanic female with 
photocoagulation treatment to control the recurrence of vitreous haemorrhage.  
Our results revealed that stabilization of the disease and improvement in visual acuity were achieved 
without any signs of recurrence. Intravitreal bevacizumab in combination with photocoagulation treatment 
of ischemic retinal areas may be a good alternative for patients with recurrent vitreous haemorrhage due 
to Eales disease. 
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INTRODUCTION 
Eales disease (ED) is a vasoproliferative retinal disease 
characterized by progressive peripheral retinal capillary 
closure resulting in increasing retinal non-perfusion, 
ischemia, and neovascularization. The pathogenesis of 
ED has not completely understood. However, it involves 
extensive retinal ischemia, resulting in the release of 
angiogenic factors such as the vascular endothelial 
growth factor (VEGF) [1,2]. 
Bevacizumab (Avastin®), a full-length humanized 
monoclonal antibody that binds to all VEGF-A isoforms is, 
at present, one of the most effective treatments for 
neovascular conditions such as age-related macular 
degeneration and proliferative diabetic retinopathy. We 
report the a 56-year old female  with rubeosis iridis and 
retinal neovascularization due to ED who was treated 
with a combination of retinal photocoagulation and 
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CASE REPORT 
A 56-year old Hispanic woman experiencing blurred 
vision in her right eye consulted our retina department in 
August 2006. She had previously suffered from vitreous 
hemorrhage which had resolved spontaneously in both 
eyes for 3 years duration. At the time of her first visit, 
she was treated with beta-blockers and prostaglandin 
analog eye drops for bilateral chronic open angle 
glaucoma diagnosed 8 years ago. Her corrected visual 
acuity (BCVA) was 20/60 in her right eye (OD) and 20/30 
in the left one (OS). Slit lamp biomiscroscopy, revealed 
the presence of tiny, neovascular, dilated capillary tufts 
at the pupillary margin (rubeosis iridis) in her OD. The 
intraocular pressure (IOP) has been measured within 
normal limits in both eyes (16 mmHg).  Dilated fundus 
examination revealed a peripheral vascular sheating at 
the temporal vascular zone in both eyes.  Fine solid white 
lines, representing obliterated larger vessels as well as 
vitreous hemorrhage were detected in the right eye. 
 
Figure 1: Fluorescein angiography shows leakage from the suspected 
new vessels with peripheral capillary non-perfusion. 
 
Retinal neovascularization visualized bilaterally and 
retinal scars from previous laser photocoagulation 
treatment were present in areas of the temporal vascular 
retina in both eyes. Leakage from suspected new vessels 
together with peripheral capillary nonperfusion area was 
noted in fluorescein angiography (Figure 1). A diagnostic 
laboratory evaluation was performed including: routine 
tests (complete blood count, erythrocyte sedimentation 
rate, blood sugar, protein electrophoresis, blood 
chemistry, chest X-ray, urinalysis, C- reactive protein), 
infectious disease laboratory (VDRL, FTA-ABS, PPD and 
Brucella titer) and systemic autoimmune disorder tests 
(antinuclear antibody, anti-double stranded DNA 
antibodies, ANCA, C3 and C4). All of the values were 
within normal limits.  
A mantoux test showed lightly positive result. Since in 
Argentina almost all citizens have been immunized for TB 
with a BCG vaccination, we considered this measurement 
as a negative value. The patient was diagnosed as Eales 
disease due to the absence of a cause for the retinal 
vascular disease.  
As the patient preferred not to undergo a new proposed 
laser treatment in the OD, an intravitreous bevacizumab 
(1.25 mg/0.05 ml) (Avastin® Roche Argentina) was 
applied. The treatment was carried out and subsequently 
almost seven days following the procedure an 
improvement in the iris and retinal neovascularization 
with the improvement in vision to 20/25 has been 
noticed. Subsequently, in March 2007 she presented 
with a vitreous hemorrhage in the contralateral eye. The 
visual acuity dropped to 20/70 and she has received an 
intravitreal Avastin® in the OS. A subsequent 
improvement of her visual acuity was initially detected 
but 2 months later recurrent hemovitreous had returned 
to the same eye. A second application of bevacizumab 
(Avastin®) was administered. This time, seven days after 
bevacizumab application, laser photocoagulation 
treatment was performed over the ischemic areas of the 
left eye. After four years follow-up her BCVA was 
detected to 20/30 OD and 20/70 OS with regressed 
rubeosis iridis, IOP readings of 18 (OD) and 17 mmHg 
(OS) and mild nuclear sclerosis. A fundus examination 
revealed no retinal neovascularization or vitreous 
hemorrhage. Furthermore, due to financial difficulties 
either OCT or new Angiography were not performed. The 
follow-up was performed every 6 months and she did not 
present any sign of other problems at the time of visit. 
 
DISCUSSION 
ED is an idiopathic obliterative vasculopathy. Clinical 
findings are characterized by avascular areas in the retina 
periphery followed posteriorly by microaneurysms, 
dilatation of capillary channels, tortuosity of neighboring 
vessels, and spontaneous chorioretinal scars [3]. It is a 
diagnosis of exclusion, as many other retinal disorders 
can mimic ED, especially conditions of retinal 
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inflammation or neovascularization. Visual compromise 
is seen in patients with recurrent vitreous hemorrhage, 
but resolves to better than 20/200 in greater than 70% of 
patients. If retinal nonperfusion extends into the macula, 
the visual acuity usually is worse than 20/400. Often, 
patients complain of uniocular symptoms, but 
ophthalmic examination reveals changes of ED in the 
other eye like our patient. Bilateral involvement is 
evident in 80-90% of patients. Neovascularization of the 
disc (NVD) or neovascularization elsewhere (NVE) was 
observed in up to 80% of patients with ED [4].  
The NVE usually is located peripherally, at the junction of 
perfused and nonperfused retina. The neovascularization 
often is the source of vitreous hemorrhage in these eyes, 
compromising vision. Rubeosis iridis or 
neovascularization of the iris can develop and may lead 
to neovascular glaucoma. The pathogenesis of ED 
involves extensive retinal ischemia resulting in the 
angiogenic factors, such as IL-6, IL-8, MCP-1, and VEGF, 
which were previously found in the vitreous of patients 
with Eales disease by Murugeswari et al [5].  
Neovascularization from the disc (NVD) or elsewhere 
(NVE) in the retina is observed in up to 80% of patients 
with ED, with retinal neovascularization often being the 
source of vitreous hemorrhage in these eyes. Current 
treatment options for ED include intraocular steroids [6], 
retinal photocoagulation to the non-perfused retina, and 
early vitrectomy for recurrent vitreous hemorrhage [7]. 
However, some recent articles have suggested 
intraocular bevacizumab as a new form of treatment in 
neovascular ED [8,9,10] or as a possible adjunctive 
treatment to vitreoretinal surgery for the management 
of ED with tractional retinal detachment [11]. 
However, this treatment has a legacy of serious 
complications. Recently, Kumar A et al reported four out 
of fourteen patients who had received pretreatment with 
intravitreal bevacizumab (0.25 mg) and subsequently 
underwent a pars plana vitrectomy for non-resolving 
vitreous hemorrhage and/or tractional retinal 
detachment developed secondary rhegmatogenous 
retinal detachment, within a week of receiving 
intravitreal bevacizumab [12]. Similar results were found 
recently by Patwardhan SD, et al [13].  It seems this kind 
of complication could happen also to patients with Eales 
along with vitreous hemorrhage or mild bleeding. But 
these kinds of complications presumably could be 
avoided if laser photocoagulation was made prior to 
intraocular bevacizumab treatment in the entire 
peripheral ischemic retina. In our patient, intravitreal 
anti-VEGF therapy alone was not sufficient to control the 
disease and combination therapy of laser treatment and 
intraocular bevacizumab was effective in improving and 
stabilizing her vision.   
In conclusion, our case suggests that combined laser 
therapy and intraocular anti-VEGF therapy may be 
necessary for the control of neovascularization, leading 
to an improvement of visual acuity in patients with 
complicated ED. A close follow-up for the early detection 
of recurrent neovascularization and subsequent prompt 
treatment may improve the visual outcomes in such 
patients. Furthermore, more trials should be conducted 
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